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Objective: To characterize disease evolution in amyotrophic lateral sclerosis
using an event-based model designed to extract temporal information from
cross-sectional data. Conventional methods for understanding mechanisms of
rapidly progressive neurodegenerative disorders are limited by the subjectivity
inherent in the selection of a limited range of measurements, and the need to
acquire longitudinal data. Methods: The event-based model characterizes a dis-
ease as a series of events, each comprising a significant change in subject state.
The model was applied to data from 154 patients and 128 healthy controls
selected from five independent diffusion MRI datasets acquired in four different
imaging laboratories between 1999 and 2016. The biomarkers modeled were
mean fractional anisotropy values of white matter tracts implicated in amy-
otrophic lateral sclerosis. The cerebral portion of the corticospinal tract was
divided into three segments. Results: Application of the model to the pooled
datasets revealed that the corticospinal tracts were involved before other white
matter tracts. Distal corticospinal tract segments were involved earlier than
more proximal (i.e., cephalad) segments. In addition, the model revealed early
ordering of fractional anisotropy change in the corpus callosum and subse-
quently in long association fibers. Interpretation: These findings represent
data-driven evidence for early involvement of the corticospinal tracts and body
of the corpus callosum in keeping with conventional approaches to image anal-
ysis, while providing new evidence to inform directional degeneration of the
corticospinal tracts. This data-driven model provides new insight into the
dynamics of neuronal damage in amyotrophic lateral sclerosis.
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
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Introduction
Amyotrophic Lateral Sclerosis (ALS) is now recognized as
both a clinically and pathogenically heterogeneous disor-
der.1 This poses new challenges for understanding disease
evolution in relation to the underlying molecular and cel-
lular mechanisms of neurodegeneration.
Thus far, schemes for studying the evolution and stag-
ing of these diseases have depended on the selection of
phenotypic and biomarker criteria (broadly defined to
include a wide range of clinical, molecular, and neu-
roimaging measures). Examples include the King’s and
MiToS systems for clinical in vivo staging2,3 that prede-
fine milestones representing stages by involvement of
body regions and by functions. The Braak postmortem
histopathological staging schemes4,5 applied to Alzhei-
mer’s disease and ALS, depend on a priori assumptions
on the pattern of pathological change, which are by defi-
nition end-stage. In this latter context, the notion of stage
is necessarily an inference from the observed patterns of
pathological change. The same caveat applies to neu-
roimaging staging systems that (for example) select cer-
tain tracts for analysis (e.g.6) based on similar a priori
assumptions derived from the postmortem model. Subjec-
tive inferences must be drawn regarding disease spread,
since it is conceivable that the areas in which changes
appear over time were affected at baseline, but at a level
below detection by the techniques applied. In other
words, there is a problem of sensitivity and selection of
criteria of change, even in longitudinal neuroimaging
studies. In addition, missing data7,8 is likely to introduce
bias into longitudinal analyses since missingness is unli-
kely to be random in ALS.9
In order to address these problems, a number of data-
led approaches have been developed, but are as yet not
integrated into prospective phenotyping studies or clinical
trials. In ALS, a data driven study using latent class clus-
ter analysis has identified prognostic and clinical sub-
groups that are distinct from those derived from analyses
based on subjective clinical subgroupings.10 More ambi-
tious data-driven models have been developed to under-
stand the sequence of biomarker changes in Alzheimer’s
disease11–15 and Huntington’s disease:11 probabilistic gen-
erative models are designed to provide a natural staging
scheme while also characterizing the uncertainty of the
ordering of biomarkers without requiring a priori clinical
diagnostic information or explicit biomarker threshold
criteria.
Here, we report the application of a probabilistic
event-based model (EBM)11,12 to ALS. Our aim was to
adapt the EBM of 12 for application to ALS and here we
describe that modeling process. We then tested the ALS
EBM model on a specific imaging parameter as ‘proof of
concept’; while previous EBM studies have modeled volu-
metric, cortical thickness, or connectivity changes, we
chose fractional anisotropy (FA) derived from diffusion
MRI, as this is the quantitative MRI modality that has,
overall, revealed the most consistent changes in ALS to
date.16 Although we selected the key white matter path-
ways for inclusion in our analysis based on existing neu-
roimaging studies, it is important to emphasize that, in
keeping with this being an unbiased approach, we had no
a priori hypothesis about the expected ordering of
involvement of these cerebral white matter tracts.
Materials and Methods
Data description
Five datasets were available for use in this study. Set E
was acquired on a GE Signa Horizon HDxt 1.5T clinical
scanner (General Electric, Waukesha, WI) at the Brain
Research Imaging Centre, University of Edinburgh
between 2010 and 2012. The diffusion MRI protocol con-
sisted of seven T2-weighted (b 0 s mm2) and sets of
diffusion-weighted (b = 1000 s mm2) whole brain sin-
gle-shot spin-echo echo-planar imaging (EPI) volumes
acquired with diffusion encoding gradients applied in 64
noncollinear directions.17 The acquisition parameters
were: (1) field of view 256 9 256 mm; (2) imaging
matrix 128 9 128; and (3) 72 9 2 mm thick contiguous
axial slice locations giving 2 mm isotropic voxels. The
repetition and echo times for the single-shot spin-echo
EPI sequence were 16.5 sec and 98.3 msec respectively.
Sets F and K were acquired between 1999 and 2011 at
the Centre for Neuroimaging Sciences, King’s College
London. Set F was obtained on a 1.5T GE Signa HDx sys-
tem (General Electric, Waukesha, WI). The protocol
included diffusion-weighted EPI with diffusion gradients
applied along 64 directions and maximum b-value of
1300 s mm2. Each volume was acquired using a multi-
slice peripherally gated doubly refocused spin echo EPI
sequence, from 60 contiguous near-axial slice locations
with anisotropic (1.875 9 1.875 9 2.5 mm) voxels. The
echo time was 101.3 msec, while the effective repetition
time varied between subjects in the range 12 and 20 RR
intervals, depending on individual participants’ heart
rates. Set K was obtained on a 3T GE Signa HDx system
(General Electric, Waukesha, WI) between 2008 and 2011.
The protocol included diffusion-weighted EPI, with diffu-
sion gradients applied along 32 noncollinear directions
and maximum b-value of 1300 s mm2. Each volume
was acquired using a multislice peripherally gated doubly
refocused spin echo EPI sequence, from 60 contiguous
near-axial slice locations with 2.4 mm isotropic voxels.
The echo time was 104.5 msec, while the effective
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repetition time varied between subjects in the range 12
and 20 RR intervals, depending on individual partici-
pants’ heart rates. Full image acquisition details are given
in.17
Set N was obtained on a 1.5T Siemens Avanto system
(Siemens AG Medical Solutions, Erlangen, Germany) at
the Clinical Imaging Sciences Centre, Brighton and Sussex
Medical School between 2014 and 2016. Multishell diffu-
sion-weighted images were acquired with single-shot,
twice-refocused pulse-gradient spin-echo EPI, using three
b-values (nine directions with b = 300 s mm2, 30 direc-
tions with b = 800 s mm2, and 60 diffusion directions
with b = 2400 s mm2), optimized for neurite orientation
dispersion and density imaging (NODDI).18 Ten nondif-
fusion weighted (b = 0) volumes were acquired. A parallel
imaging (GRAPPA) speed up factor of 2 was used; echo
time/repetition time = 99 msec/8400 msec; 2.5 mm iso-
tropic voxel size. Full image acquisition details are given
in.19
Set O was obtained on a 3T Siemens Trio scanner (Sie-
mens AG Medical Solutions, Erlangen, Germany) at the
Oxford Centre for Clinical Magnetic Resonance (OCMR)
between 2009 and 2013, as part of the Oxford Study for
Biomarkers in MND (“BioMOx”). The protocol included
diffusion-weighted whole-brain EPI, with diffusion gradi-
ents applied along 60 isotropic directions and maximum
b-value of 1000 s mm2; echo time/repetition
time = 94 msec/10,000 msec; 2 mm isotropic voxel size.
Four nondiffusion weighted (b = 0 s mm2) volumes
were acquired. Full image acquisition details are given
in.7
Specific eligibility criteria for Sets E, F, K, N, and O
are given in;7,19–22 at the time of enrollment, all patients
were systematically screened for cognitive impairment.
Only patients with a diagnosis of probable or definite
ALS were selected for inclusion in this study. One
patient was removed from Set E, due to fulfilling the
criteria for possible behavioral variant FTD. Seven and
three participants were removed from Sets F and K,
respectively, due to poor image quality. Eighteen patients
were removed from Set O due to having a diagnosis dif-
fering from probable or definite ALS. Two controls were
removed from Set O due to their young age. Basic
demographic and clinical characteristics of all five data-
sets as included in this study are summarized in
Table 1.
Magnetic resonance imaging analysis
All diffusion-weighted EPI volumes were corrected for
involuntary motion and eddy current distortions using
affine registration and the FMRIB’s Linear Registration
Tool (FLIRT), included in FSL 5.0.7, which is
documented and available freely online (https://fsl.fmrib.
ox.ac.uk). The images were skull-stripped using FMRIB’s
Brain Extraction Tool (BET). All datasets were manually
inspected for low signal to noise ratio and movement
artifacts.
For all diffusion imaging analysis, the single tensor
(ST) model was used to derive FA measurements. The ST
model was fitted with weighted least squares, using
FMRIB’s dtifit.
Normalization into MNI space was performed using
ANTs 2.1.0, which is documented and available freely
online (http://stnava.github.io/ANTs/). A study-specific
template was created for each of the five datasets. Each
subject’s FA map was warped to the corresponding tem-
plate, and all templates were warped to the JHU ICBM-
DTI-81 FA 1 mm atlas,23 included in FSL 5.0.7. These
warps were combined to produce a single warp for each
subject, which was then applied to their FA map.
To reduce the impact of scanner and site effects, the
FA voxel data were harmonized using the ComBat statis-
tical approach. ComBat is a batch adjustment method
developed for genomics data and adapted for diffusion
MRI.24 Age and patient/control status were included as
covariates during the harmonization process.
A two-tailed t-test (equal variances) for the combined
cohorts for the difference in mean age between controls
and patients showed P = 0.053. A voxel-based analysis
was therefore performed to model and correct for the
effects of age on FA, using the existing normalization. A
generalized linear model was fitted to the FA data of con-
trols only, using SPM12 (r7487). The effects of age were
regressed out of the FA maps, and the mean regional val-
ues that entered the EBM were computed from the resid-
ual images.
Event set
Seven white matter (WM) tracts were selected for analysis
(Table 2, Fig. 1) based on their likely involvement in ALS
pathology from analysis of the pathological and neu-
roimaging literature. ALS diffusion tensor imaging (DTI)
studies have most consistently reported that finding
decreased FA within the corticospinal tracts (CST).16,25,26
Multiple DTI studies have reported FA decreases in the
corpus callosum (CC),27–31 with the strongest FA
decreases appearing to be located in the middle-posterior
parts of the CC, which link the motor and premotor cor-
tices.30
Other WM regions are less consistently reported in
ALS DTI studies. Significant changes of DTI metrics
within the CST, CC, and superior longitudinal fasciculus
(SLF) have been found to correspond with a higher bur-
den of upper motor neuron (UMN) involvement in
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sporadic ALS patients.32 Decreased FA has also been
demonstrated in the uncinate fasciculus (UF).33
Diffusion tensor tractography techniques have demon-
strated correlations between performance in cognitive
tasks and DTI changes in the CC, CST, and major long-
range association tracts: the cingulum, inferior longitudi-
nal fasciculus (ILF), inferior fronto-occipital fasciculus
(IFOF), and UF.34
For each fiber bundle, region of interest (ROI) masks
were created from the JHU DTI-based white-matter trac-
tography atlases23 included in FSL 5.0.7. The ROI masks
for the CST, IFOF, ILF, and SLF were created from the
JHU white-matter tractography atlas, thresholded at 50%;
all other ROI masks were created from the ICBM-DTI-81
atlas. FMRIB’s fslstats was used to calculate mean FA val-
ues for each ROI, and these values were used as biomar-
ker readings.
To allow the investigation of a directional progression
of ALS WM neurodegeneration, the CST was split in the
inferior to superior direction. The boundaries were set at
boundaries of the posterior limb of the internal capsule
as given in the ICBM-DTI-81 atlas (MNI z-axis coordi-
nates: CST inferior z ≤ 5, CST middle  4 ≤ z ≤ 18
and CST superior 19 ≤ z). The CC was divided into three
ROIs, consisting of body, genu, and splenium, using the
JHU atlas boundaries.
Subdividing the CST and CC created a total of 11 WM
regions, each of which comprised a tract ROI combined
across both cortical hemispheres. To allow for investiga-
tion of bilateral asymmetry in ALS progression, all tracts
apart from the CC were further subdivided by cortical
hemisphere, giving a second set of 19 WM regions from
which FA biomarker values were derived. The EBM was
applied separately to both sets of biomarkers.
The event-based model
We estimated the most likely ordering of events and their
uncertainty across the cohort, using a version of the EBM
adapted for ALS. The EBM defines a disease as a series of
events, where an event is the change of a biomarker from
a “healthy” state to a “diseased” state. The cut-off point
determining this change for each biomarker is not deter-
mined a priori, but instead derived from the biomarker
data during the modeling process. Full mathematical
details of the EBM are given in11,12 and briefly summa-
rized below.
Fitting the EBM to the data requires evaluating the
likelihood P(S|X) of a particular event ordering S given
the data X. For biomarker i and patient j, this is achieved
by fitting simple models for the likelihood function P(xij|
Ei) on the measurement xij given that event Ei has
occurred, and similarly P(xij|pEi) on the measurement xij
given that event Ei has not occurred. These simple models
are derived from a two-component Gaussian mixture
model, fitted to each biomarker.
It is important to highlight some differences between
our approach and previous applications of the EBM.
First, we applied the model to data from ALS patients.
The ALS patient population is clinically distinct from the
control population; this may not apply to dementia, in
which there is likely to be a continuum in biomarker dis-
tribution between normal aging and symptomatic
Table 1. Demographics at time of neuroimaging for the five datasets E, F, K, N, and O.
Demographics Set E Set F Set K Set N Set O
Controls N 30 22 24 23 29
Gender (M/F) 16/14 (53%) 14/8 (64%) 19/5 (79%) 14/9 (61%) 14/15 (48%)
Age at scan (years, mean  SD) 59.1  11.5 49.8  15.6 47.3  8.2 61.5  9.3 52.5  11.7
ALS N 29 35 28 23 39
Gender (M/F) 16/13 (55%) 20/15 (57%) 25/3 (89%) 16/7 (70%) 25/14 (64%)
Age at scan (years, mean  SD) 58.3  11.3 54.0  12.1 52.6  11.8 64.3  8.0 57.6  10.5
Age at onset (years, mean  SD) 57.4  9.9* 51.2  13.4** 50.5  11.8 62.0  8.1 54.9  11.0
ALSFRS-R score (mean  SD) 38.8  6.9 37.7  6.6** 40.6  4.1 40.0  5.2 33.9  5.4
*N = 28.
**N = 27.
Table 2. White matter regions selected for analysis.





Cingulum (dorsal section) Cingulum 7
Superior longitudinal fasciculus SLF 8
Inferior longitudinal fasciculus ILF 9
Inferior fronto-occipital fasciculus IFOF 10
Uncinate fasciculus UF 11
With the exception of the corpus callosum, all tracts were further sub-
divided by hemisphere. Biomarker readings were taken as the mean
FA value of each region.
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disease.35 This distinction allowed for constraining the
mixture fitting: a Gaussian distribution was fitted to
the control data, and the 95% confidence intervals of the
resulting parameters were used as constraints for the first
mixture model component. The second model compo-
nent and mixing proportion were left unconstrained. Fol-
lowing the fitting, the components were separated and
used to model P(xij|Ei) and P(xij|Ei) respectively.
Second, we used FA as a biomarker, as opposed to
volumetric and cortical thickness measures11,12,15 or con-
nectivity.36 The EBM is potentially sensitive to individual
variation of biomarker readings, due to its dependence
on Gaussian mixture models, the fitting of which can be
biased by the presence of outliers. This is particularly
important when using biomarkers such as FA, which is
susceptible to noise and varies between anatomical
regions.37 To reduce the effects caused by outliers, the
mixture models were fitted 1000 times from boot-
strapped samples. Samples for which the mixing propor-
tion had collapsed to 0 or 1 were then excluded to avoid
biologically unrealistic solutions. The mixing proportion
of ILF (right hemisphere) was constrained to be >0.5, in
order to prevent consistent fitting failure. To obtain the
final mixture model parameters, the median of the
remaining bootstrapped parameters was taken. This is an
addition to the EBM which was not used in previous
applications.
Following the fitting of the mixture models, estimation
of the most likely ordering of events (the “inferred event
order”) and characterization of their uncertainty was per-
formed using a Markov chain Monte Carlo (MCMC)
algorithm to sample from the posterior event distribution
P(S|X). We note that the MCMC sampling was performed
on only the patient biomarker data, as justified by the
clinically distinct control and patient populations of ALS.
Finally, cross-validation was performed as described in
12,15 with the mixture models and the most likely event
sequence re-estimated for a further 10,000 bootstrap sam-
ples. Two further weak constraints were used during
cross-validation: mixing proportions were constrained to
be ≥ 0.01 and ≤ 0.99, and for the second model compo-
nent, the standard deviation r was set to be ≥ 0.001. For
each sample, the mixture models were directly fitted with-
out further bootstrapping, in order to minimize the risk
of underestimating the cohort variability. Cross-validation
overstates the uncertainty of the inferred event order, giv-
ing a more conservative picture than that of the MCMC
samples.
Ethics approval
All participants gave written informed consent at inclu-
sion, in accordance with the Declaration of Helsinki.
Participants in Sets E, N, and O explicitly gave consent
for their data to be used in further studies. We
obtained additional ethical approval to use participant
data from Sets F and K in this study from NRES
Committee London – Stanmore (REC reference 14/LO/
1484).
Results
Inferred order of events – combined
hemispheres
Figure 2A is a positional variance diagram, showing the
inferred order of events on the y-axis (top to bottom),
and each event’s variation across the MCMC samples.
This variation may be considered to represent the uncer-
tainty of an event’s ordering, and is represented by the
intensity of each square: higher certainty corresponds to
darker squares.
The event sequence shows with high confidence that
the earliest changes detected are in the CSTs and CC
body; the distal CST is more susceptible to MRI degener-
ative change than the proximal segment as reflected by
changes in FA in the three segments of the CSTs. The
next regions affected are the CC splenium and body,
which are followed by a cluster comprised of the SLF,
ILF, and cingulum. The final ROIs to be affected are the
IFOF and UF.
We note that the inferred event sequence shows fibers
ordered by type; projection fibers are the first affected,
followed by commissural fibers, and finally long associa-
tion fibers.
Cross-validation reveals a similar picture, with
increased uncertainty across all biomarkers (Fig. 2B). The
CST biomarkers are the events with the highest positional
confidence, reflecting the CST’s role as the tract most
consistently implicated in ALS DTI studies.
Inferred order of events – separate
hemispheres
Qualitatively, the inferred order when considering hemi-
spheres separately (Fig. 2C) is broadly similar to that for
the combined hemispheres (Fig. 2A), although there are
differences within the ordering of the association fibers.
Again, the distal over proximal degeneration of the CSTs
is apparent, with the event sequence not favoring one
hemisphere over another; i.e., showing no clear evidence
for bilaterally asymmetric progression within the CSTs.
We note that ILFR required an extra constraint during
mixture fitting to avoid consistent fitting failure; the need
for this constraint may indicate reduced accuracy of tem-
poral staging for this biomarker.
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As before, cross-validation (Fig. 2D) shows similar
event positional variance, albeit with increased uncer-
tainty across all biomarkers; the positional uncertainty is
greatest for the long association fiber regions and the
extremities of the CC, qualitatively corresponding with
the increased variability seen in Figure 2B.
Imaging biomarker staging
The EBM also possesses fine-grained staging capabili-
ties,12,15 whereby each person is assigned a biomarker
stage that best reflects their measurements. In order to
maximize the accuracy of stage assignment, we applied
the staging process to the combined hemisphere biomar-
ker set, as this has the most distinct event ordering. The
staging proportions for all participants are shown in Fig-
ure 3, differentiated by control/patient status. Unlike pre-
vious applications of the EBM to Alzheimer’s disease, we
do not find strong separation between the diagnostic
groups (i.e., patients and controls) when performing this
subject-specific staging. We note that most previous
applications of the EBM leave out biomarkers that do not
show statistically significant differences between patients
and controls. However, our aim here is more to elucidate
the sequence of change than to stage patients so we retain
all biomarkers, but acknowledge that the ordering may
not be reliable for markers that do not discriminate
patients and controls.
Discussion
Using an event-based probabilistic model developed for
ALS on the basis of similar approaches in Alzheimer’s
disease and Huntington’s disease,11,12 we infer a temporal
susceptibility of MRI-based pathological involvement in
key white matter pathways in ALS, using FA as a biomar-
ker of axonal damage.
Our main findings can be summarized as follows. First,
the model suggests that the earliest detectable MRI-based
intracerebral white matter FA changes are in the CSTs.
Second, FA changes in the CSTs may have a directional
susceptibility, with FA changes occurring distally prior to
proximally. Third, the CC is involved next in sequence to
the CSTs, with detectable FA changes occurring in the CC
body, then in the splenium and finally in the genu.
Fourth, the long association fiber tracts are affected after
the CSTs and CC body. Fifth, we have found that sub-
ject-specific staging reveals a significant overlap between
controls and ALS patients.
Regarding the CSTs, all longitudinal MRI studies to
date identify this as the earliest white matter tract in
which MRI-based abnormalities are detectable,16 in keep-
ing with the outcome of our EBM. However, our observa-
tions suggest that the pathological dynamics affecting the
CSTs is a ‘dying-back’ process or distal axonopathy.38
Classical histopathology cannot, by definition, identify
dynamic aspects of CST degeneration, but in accord with
our findings pathological changes along the proximal-dis-
tal are usually more evident in distal compared to more
proximal portions of the pathway,39 and in keeping with
a so-called ‘dying-back’ process. There has been much
debate as to whether the degenerative process is driven by
changes in the primary motor cortex as an anterograde
form of neurodegeneration or is retrogradely initiated
from somatic motor neurons.40 However, this dualism is
likely to be misleading, since the perikaryon, dendrites,
Figure 1. White matter regions selected as biomarker regions (only the left hemisphere portions are visible). 3D render of the ROI masks in MNI
space; each cube is equal to a 1mm isotropic voxel. 1–3 = corticospinal tract inferior/middle/superior, 4–6 = corpus callosum genu/body/splenium,
7 = cingulum, 8 = superior longitudinal fasciculus, 9 = inferior longitudinal fasciculus, 10 = inferior fronto-occipital fasciculus, 11 = uncinate
fasciculus.
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and axon form a unified functional and, presumably,
pathophysiological unit. Data-driven approaches to old
controversies may help to resolve this issue, if indeed it is
a meaningful dichotomy.
Likewise, involvement of the CC has been a consistent
finding in MRI studies in ALS.7,30,32 In the EBM, the stag-
ing of CC involvement evolved from the body, to the sple-
nium and the genu. This is in keeping with the notion that
the callosal fibers most affected in ALS are those that con-
nect the primary motor areas of the hemispheres.41 The
EBM results are broadly keeping with the Braak staging sys-
tem5 regarding the CSTs and CC. However, in contrast
with recent studies6,8,26 that have sought to confirm this
pathological staging system using cross-sectional and longi-
tudinal neuroimaging data, our EBM makes no a priori
assumptions on the ordering of white matter involvement.
Figure 2. Event-based models of amyotrophic lateral sclerosis progression. Positional variance diagrams (PVDs) for (A,B) 11 white matter regions
(combined across cortical hemispheres) and (C,D) 19 white matter regions (subdivided by cortical hemisphere). The inferred event order is given
along the y-axis (top to bottom). The grayscale intensity of each square is proportional to the posterior confidence with which a biomarker
occupies a position in the event sequence; higher intensity corresponds to lower positional variance and thus greater confidence. Left: PVDs of
MCMC samples from the event-based model. Right: PVDs from cross-validation through bootstrapping. These diagrams overstate the uncertainty
of the inferred event order, giving a more conservative picture than that of the MCMC samples. CST = corticospinal tract, CC = corpus callosum,
Cingulum = cingulum (dorsal section), IFOF = inferior fronto-occipital fasciculus, ILF = inferior longitudinal fasciculus, SLF = superior longitudinal
fasciculus, UF = uncinate fasciculus. Inf/mid/sup = inferior/middle/superior, L/R = left/right hemisphere.
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Turning to the other white matter tracts included in
our modeling: the cingulum, SLF, ILF, IFOF, and UF
have all been identified as showing changes in DTI met-
rics in ALS.32–34 Furthermore, their involvement has been
linked to cognitive changes across several domains includ-
ing attention and executive functions,22,34,42 and language
processing (the ILF, IFOF and UF).42–45 The ordering of
these long association fibers comprises the main differ-
ences between the inferred event orders for combined and
separate hemispheres (Fig. 2A and C). The involvement
of these tracts in ALS DTI studies is less consistently
reported than the CSTs and CC,16,25–31 suggesting a smal-
ler effect size and greater heterogeneity of FA values
within the long association fiber ROIs; the differences in
inferred event orders may be reflective of this. An alterna-
tive explanation is the reduced signal-to-noise ratio in the
case of separate hemisphere ROIs.
Our selection of white matter tracts could be criticized
in that we did not include in our EBM specific pathways
that have been prioritized on the basis of the pathologi-
cally based hypothesis of disease spread.5,6,26,46 We had
reservations about the self-fulfilling nature of the selection
based on this hypothesis and chose to focus initially on
the pathways identified in studies not based on this
presupposition.7,32,34 However, it will be important to
add these pathways to the model in future applications
and developments of the EBM.
The mean FA values were extracted using atlas-defined
ROIs; this approach relies on registration to standard
space and does not account for individual anatomical dif-
ferences. An alternative approach is to use tractography
to reconstruct the tracts of interest on a participant-wise
basis. Tractography, however, is strongly affected by data
acquisition parameters, such as maximum b-value and
number of diffusion directions. Given the variability in
the acquisition protocols used for the datasets included in
this study, we opted for minimizing the bias using prede-
fined ROIs.
As well as finding the most likely event order, the EBM
is capable of staging disease progression in fine detail.
Unlike previous applications of the EBM to Alzheimer’s
disease, we find poor separation between the diagnostic
groups (i.e., patients and controls) when performing this
subject-specific staging. The assignment of controls to late
biomarker stages is likely due to the limited sensitivity
and specificity of FA as a biomarker for ALS.16 DTI is
limited in its sensitivity to tissue microstructure47 and
more sophisticated approaches, such as NODDI, could
Figure 3. Proportion of patients and controls allocated to each biomarker stage by maximum likelihood. The stages are in the same order as
given in Figure 2A.
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improve on these results. However, as this study relied on
historical data it was not possible to use such approaches.
Future studies employing biomarkers with greater diag-
nostic accuracy should be able to demonstrate improved
separation between ALS patients and controls.
By setting Stage 1 as the cut-off point (i.e., Stage
0 = healthy, Stage 1 and above = ALS), the subject-
specific staging distinguished between patients and con-
trols with a sensitivity of 66.9% and specificity of
75.8%. This is comparable to that of other FA-based
ALS biomarkers.48 The proportions of participants
assigned to various biomarker stages are also informa-
tive: Figure 3 shows that 33.1% of patients are assigned
to biomarker stage 0, equivalent to none of the included
biomarkers being in a diseased state. While the hetero-
geneity of ALS should be considered as a causal factor,
another plausible explanation is that relevant biomarkers
have not been included in this analysis; i.e. this biomar-
ker staging could suggest that detectable changes in the
mean FA of the CSTs do not represent the beginning of
ALS pathology.
The EBM method is subject to the difficulties inherent
in any data-driven approach: the model finds patterns
within the data, and these patterns require interpretation
within the context of the pathology of the disease. More-
over, the probabilities are based on the variable sensitivity
of water diffusion-based metrics, which are known to vary
physiologically along the length of many tracts, and are
influenced by crossing fibers.49 Any interpretation must
be subjective to a certain degree, particularly when estab-
lishing the biological significance of the modeling output,
given that the precise relationship between MRI metrics
and histology is still being uncovered.50 Likewise, as with
any modeling process, simplifications and assumptions
about the disease process are unavoidable. In particular,
the EBM assumes that the event sequence is consistent
over all patients, which is unlikely to hold for a heteroge-
neous disease such as ALS. We have tried to mitigate the
impact of disease heterogeneity by using bootstrapping to
fit the mixture models, thus reducing the effects of indi-
viduals and giving an “average disease progression” across
the entire cohort.
As with any data-driven method, sample size and
heterogeneity must be taken into consideration when
drawing conclusions; the clinical cohorts available to us
were relatively small, which warrants caution when gener-
alizing results beyond this study. While the cohorts show
differences in demographic and prognostic characteristics,
especially age and gender distribution, such variations are
unlikely to invalidate the analysis of tract involvement in
the context of EBM but might contribute to greater vari-
ability in the ordering of events. It is therefore all the
more striking that the ordering of change in FA along the
CSTs is highly consistent, as is the involvement of the
CC. Finally, historical cohorts such as ours pose chal-
lenges derived from older technology and lack of stan-
dardization of scanning protocols between cohorts.
In summary, we have adapted the EBM and applied it
to five independent ALS cohorts, using FA as the most
robust measure of white matter damage in this disease.
The model clearly and consistently demonstrates the
dynamic of pathological involvement in ALS, which is in
keeping with known pathological processes derived from
more subjective approaches.7 Having shown here that the
EBM can be applied to a relevant biomarker in ALS, the
next stage will be to take a more inclusive approach
incorporating a much wider range of biomarkers. The
field of data-driven modeling applied to progressive neu-
rological diseases is relatively new, but this study indicates
that the EBM has great potential to inform understanding
of the dynamics of the underlying biological processes in
ALS.
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